NCT05405543View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

November 16, 2022

Study Completion Date

December 9, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

MYK-224

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (1)

92801

Local Institution - 0001, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05405543 - A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants | Biotech Hunter | Biotech Hunter